KaliVir Immunotherapeutics has closed a $14 million extension to its Series A financing, led by Company K Partners with participation from SV Investment and Flexus Partners. This funding will advance its lead oncolytic immunotherapy candidate, KVN201, into Phase 1 clinical trials for solid tumors. The company plans to use the capital to further develop its pipeline and expand its research and development efforts.